Keywords: Biology, Models, Methods, Multimodal, glioblastoma, MR spectroscopy, gallium, radiosensitizer
Motivation: Patients with treatment-resistant glioblastoma (GBM) have limited treatment options available to them.
Goal(s): We seek to develop an optimized imaging protocol to assess the treatment effect of the novel metallocompound, gallium maltolate (GaM) and evaluate in vivo its action as a radiosensitizer.
Approach: Our translational rat preclinical model utilizes MRI and MR spectroscopy to longitudinally monitor the treatment effect of GaM in combination with radiation therapy (RT).
Results: Combination therapy of GaM+RT in vivo results in a profound and sustained inhibition of established treatment-resistant GBM compared to monotherapy alone. This approach could dramatically change how brain tumors such as GBM are treated.
Impact: Our work seeks to shift current research and clinical practice paradigms by utilizing a novel and innovative therapeutic approach to target the iron metabolism of aggressive primary brain tumors for patients with limited treatment options.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords